People · Operator
Named in public records as an officer, director or promoter · active 2008–2023 · Pharma, Biotechnology, Pharmaceuticals, Other, Biotech / Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Pear Therapeutics, Inc. | — | Pharma | Series D+ | $254.8M | $4.1B | 2016 |
| Camp4 Therapeutics Corp | — | Biotechnology | Series D+ | $179.6M | $2.2B | 2022 |
| Millendo Therapeutics, Inc. | — | Pharmaceuticals | Series C | $106.5M | $1.8B | 2012 |
| RareCyte, Inc. | — | Other | Series B | $79.8M | $103.6M | 2019 |
| Bird Rock Bio, Inc. | — | Biotech / Pharma | Series B | $52.5M | $91.9M | 2008 |
| Precision Nanosystems Inc. | — | Biotechnology | Series A | $22.3M | $107.7M | 2015 |
| DVS Sciences, Inc. | — | Biotechnology | Series A | $4.1M | $149.4M | 2010 |
Andrew J. Schwab at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Andrew J. Schwab on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Frank J. Witney | 2 | 2 |
| Andrew Schwab | 1 | 16 |
| Amir Nashat | 1 | 14 |
| James Topper | 1 | 12 |
| Michael Higgins | 1 | 9 |
| Timothy Petersen | 1 | 9 |
| Carol Gallagher | 1 | 6 |
| Bradley J. Bolzon | 1 | 5 |
| William Burkoth | 1 | 5 |
| Brian Daniels | 1 | 5 |
| Corey McCann | 1 | 5 |
| Jorge Conde | 1 | 4 |
| Robert Shepler | 1 | 4 |
| Elena Viboch | 1 | 4 |
| Shaan Gandhi | 1 | 4 |
| Stephen W. Kaldor | 1 | 3 |
| Carole Neuchterlein | 1 | 3 |
| Frank Witney | 1 | 3 |
| William J. Harrington | 1 | 3 |
| Paula Ragan | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.